- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04497116
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a first-in-human, Phase 1/2a, multi-center, open-label, dose-escalation and expansion study to:
- Evaluate the safety profile and MTD of RP-3500 (camonsertib) when administered orally, alone and in combination with talazoparib or gemcitabine, to establish the dose and schedule recommended for the Phase 2
- Characterize the PK profile of RP-3500 (camonsertib) alone or in combination with talazoparib or gemcitabine
- Identify anti-tumor activity associated with RP-3500 (camonsertib) given alone or in combination with talazoparib or gemcitabine
- Examine biomarker responses and establish a correlation with RP-3500 (camonsertib) exposure and clinical outcomes.
The initial cohorts will test RP-3500 (camonsertib) as monotherapy. Additional cohorts will enroll with RP-3500 (camonsertib) in combination with talazoparib or gemcitabine.
After the RP2D and schedule is determined, expansion cohort(s) for RP-3500 (camonsertib) will be enrolled to study the anti-tumor effect, and further examine the safety and PK of RP-3500 (camonsertib) at the RP2D
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Gabriela Gomez, MD, MBA
- Phone Number: 857-340-5415
- Email: clininfo@reparerx.com
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Participating Site 2001
-
-
-
-
DK
-
Copenhagen, DK, Denmark, 2100 Ø
- Participating Site 4001
-
-
-
-
-
London, United Kingdom, W1G 6AD
- Participating Site 3003
-
Manchester, United Kingdom, M20 4BX
- Participating Site 3001
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- Participating Site 3002
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Participating Site 1014
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Participating Site 1006
-
Boston, Massachusetts, United States, 02215
- Participating Site 1002
-
-
New York
-
New York, New York, United States, 10065
- Participating Site 1004
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Participating Site 1005
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Participating Site 1007
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Participating Site 1003
-
-
Texas
-
Houston, Texas, United States, 77030
- Participating Site 1001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent, according to local guidelines, signed and dated by the patient or legal guardian prior to the performance of any study-specific procedures, sampling, or analyses.
- Male or female and ≥ 18 years-of-age at the time of signature of the consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Histologically confirmed solid tumors resistant or refractory to standard treatment and/or patients who are intolerant to standard therapy.
- Measurable disease as per RECIST v1.1
- Existing biomarker profile (tumor tissue or plasma) reported from a local test obtained in a certified lab per institutional guidelines:
- Available tumor tissue
- Ability to comply with the protocol and study procedures detailed in the Schedule of Assessments.
- Ability to swallow and retain oral medications.
- Acceptable organ function at screening
- Acceptable blood counts at screening
- Negative pregnancy test (serum or urine) for females of childbearing potential at Screening and prior to first study drug.
- Resolution of all toxicities of prior treatment or surgery.
- Male patients with female partners of childbearing potential and females of childbearing potential must follow a contraception method (oral contraceptives allowed) during their participation in the study and for at least 6 months following last dose of study drug. Male patients must also refrain from donating sperm during their participation in the study and for 6 months following last dose of study drug.
Exclusion Criteria:
- Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 14 days prior to first dose of study drug.
- History or current condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
- Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor.
- Known hypersensitivity to any of the ingredients of RP-3500 (camonsertib).
- Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the patient's safety.
- Uncontrolled, symptomatic brain metastases.
- Uncontrolled high blood pressure
- Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
- Moderate or severe hepatic impairment (ie, Child-Pugh class B or C).
- History or presence of an abnormal ECG that is clinically significant in the investigator's opinion.
- History of ventricular dysrhythmias or risk factors such as structural heart disease, coronary heart disease (clinically significant electrolyte abnormalities or family history of sudden unexplained death or long QT syndrome
- Current treatment with medications that are well-known to prolong the QT interval
- History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RP-3500 (camonsertib) alone
Phase 1: Multiple doses of RP-3500 (camonsertib) for oral administration alone |
Oral ATR inhibitor
|
Experimental: Expansion cohorts with RP-3500 (camonsertib)
Phase 2: Expansion cohorts with RP-3500 (camonsertib) |
Oral ATR inhibitor
|
Experimental: RP-3500 (camonsertib) with Talazoparib or Gemcitabine
Phase 1: Multiple doses of RP-3500 (camonsertib) for oral administration in combination with talazoparib or gemcitabine |
Oral PARP inhibitor
Gemcitabine
Oral ATR inhibitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To define the Maximum Tolerated Dose (MTD) which will then be used to inform and determine the Recommended Phase 2 Dose (RP2D) and schedule alone or in combination with talazoparib or gemcitabine
Time Frame: Up to 90 days after last administration of study intervention
|
Up to 90 days after last administration of study intervention
|
|
Frequency of Dose limiting Toxicities (DLTs)
Time Frame: At the end of cycle 1 (each cycle is 21 days or 28 days)
|
At the end of cycle 1 (each cycle is 21 days or 28 days)
|
|
Safety and tolerability
Time Frame: Up to 90 days after last administration of study intervention
|
Grade and frequency of adverse events and serious adverse events
|
Up to 90 days after last administration of study intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess preliminary anti-tumor activity with Overall Response Rate in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1) or confirmed response in CA-125 or PSA per GCIG or PSWG criteria.
Time Frame: About 1 year
|
Overall response rate
|
About 1 year
|
Assess preliminary anti-tumor activity with Overall Response Rate in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1)
Time Frame: About 1 year
|
Objective response rate (ORR)
|
About 1 year
|
Assess CR+PR+SD (≥ 4 months) based on RECIST v1.1, confirmed CA-125 response by GCIG criteria, or PSA response based on PCWG3
Time Frame: About 1 year
|
Clinical Benefit Rate
|
About 1 year
|
Assess preliminary anti-tumor activity with Duration of Response (DOR) in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1).
Time Frame: About 1 year
|
Duration of response (DOR)
|
About 1 year
|
Peak plasma concentration
Time Frame: Through Study Day 152
|
Cmax
|
Through Study Day 152
|
Pharmacodynamic biomarkers of DNA damage (e.g. gH2AX) will be measured by immunohistochemistry and the percentage of positive cells will be compared between the pre and post treatment biopsies to evaluate target engagement
Time Frame: Through Study Day -28 to Day 66 (each cycle is 21 days)
|
Tumor tissue samples will be collected pre and post dosing
|
Through Study Day -28 to Day 66 (each cycle is 21 days)
|
Characterize the pharmacokinetic profile of RP-3500 (camonsertib)
Time Frame: Through Study Day 152
|
Area-under-the-curve (AUC 0-inf)
|
Through Study Day 152
|
To assess PK parameters of RP-3500 (camonsertib) monotherapy in fasted and fed states
Time Frame: Through Study Day 152
|
Comparison of geometric mean ratios (GMR)
|
Through Study Day 152
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Timothy A Yap, MBBS PhD FRCP, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP-3500-01
- 2020-000301-87 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on Talazoparib
-
National Cancer Institute (NCI)Terminated
-
Center Trials & TreatmentBioGene PharmaceuticalWithdrawnBreast Neoplasm | Advanced or Recurrent Solid TumorsAlbania
-
Seoul National University HospitalRecruitingAdvanced Breast CancerKorea, Republic of
-
Samsung Medical CenterNot yet recruitingPremenopausal HR+/HER2- Metastatic Breast CancerKorea, Republic of
-
PfizerTerminated
-
PfizerCompleted
-
PfizerActive, not recruitingNeoplasms | Breast NeoplasmsJapan
-
Brown UniversityPfizer; LifespanTerminatedOvarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous CarcinomaUnited States
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
PfizerMedivation, Inc.; Myriad Genetic Laboratories, Inc.TerminatedBreast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene MutationUnited States, Spain, United Kingdom, Germany, France